Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383:2557-2570.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341-1352.
National Comprehensive Cancer Network Guidelines (NCCN Guidelines). Breast Cancer (Version 4.2023). March 23, 2023. Accessed June 18, 2023. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Cardoso F, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194-1220.
Nielsen TO, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113:808-819.
Quiet CA, et al. Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol. 1996;14:3105-3111.
Andre F, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816-1837.
Mittempergher L, et al. Performance characteristics of the BluePrint breast cancer diagnostic test. Transl Oncol. 2020;13:100756.
Paluch-Shimon S, et al. ESO-ESMO Fifth International Consensus Guidelines For Breast Cancer in young women (BCY5). Ann Oncol. 2022;33:1097-1118.
Giordano SH, et al; Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update. J Clin Oncol. 2022;40:307-309.
Johnston SRD, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90.
Johnston SRD, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Cancer Res. 2023;83(suppl):GS1-09.
Hamilton E, et al. Efficacy and safety results by age in monarchE: adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). J Clin Oncol. 2023;41(suppl 16):501.
Rugo HS, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33:616-627.
Abemaciclib [prescribing information]. Approved 2017. Revised March 2023.
Abemaciclib. European Medicines Agency EPAR-product information. Updated February 24, 2023. Accessed September 9, 2023. https://www.ema.europa.eu/en/documents/variation-report/verzenios-h-c-004302-ii-0013-epar-assessment-report-variation_en.pdf
Slamon DJ, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the phase III NATALEE trial. J Clin Oncol. 2023;41(suppl 17):LBA500.
Tutt ANJ, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405.
Geyer CE Jr, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250-1268.
Olaparib [prescribing information]. Approved 2014. Revised November 2020.
Olaparib. European Medicines Agency EPAR-product information. Updated November 2022. Accessed September 9, 2023. https://www.ema.europa.eu/en/documents/overview/lynparza-epar-medicine-overview_en.pdf
Loibl S, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol. 2021;39:1518-1530.
O'Shaughnessy J, et al. Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis. Cancer Res. 2023;83(suppl):P3-03-12.
Pan H, et al. Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: analyses of 82,598 women in the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) database. Cancer Res. 2019;80(suppl):GS2-04.
Regan MM, et al. Randomized comparisons of adjuvant exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS vs tamoxifen in premenopausal women with HR+ early breast cancer: update of the TEXT and SOFT trials. Cancer Res. 2019;80(suppl):GS2-05.

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director
Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas, United States

Disclosures

Joyce O'Shaughnessy, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Agendia; Amgen, Inc.; Aptitude Health; AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; Carrick Therapeutics; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Inc.; Fishawack Health; G1 Therapeutics; GlaxoSmithKline; Genentech; Genzyme Corporation; Gilead Sciences, Inc.; Immunomedics, Inc.; Incyte Corporation; Lilly; Merck; Novartis; Ontada; Pfizer, Inc.; Pharmacyclics, Inc.; Pierre Fabre; Puma Biotechnology; Roche; Samsung Bioepis; Sanofi; Seagen Inc.; Stemline Therapeutics; Theralink; Synthon BV

Aditya Bardia, MD, MPH

Director
Breast Cancer Research
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Aditya Bardia, MD, MPH, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; Immunomedics, Inc.; Lilly; Merck; Mersana; Novartis; Pfizer, Inc.; Philips; Radius Health, Inc.; Sanofi
Research funding from: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; Immunomedics, Inc.; Lilly; Merck; Novartis; Pfizer, Inc.; Radius Health, Inc.

Javier Cortes, MD, PhD

Head, International Breast Cancer Center (IBCC)
Medica Scientia Innovation Research (MedSIR)
Barcelona, Spain

Disclosures

Javier Cortés, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Novartis; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda
Research funding from: Novartis; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda

Editors

Victoria Phoenix, BS

Medical Education Director, Medscape, LLC

Disclosures

Victoria Phoenix, BS has no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, Medscape, LLC

Disclosures

Tristin Abair, PhD, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Implementing Therapeutic Intervention in High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Understanding the Prognostic Implications

Authors: Joyce O’Shaughnessy, MD; Aditya Bardia, MD, MPH; Javier Cortés, MD, PhD
CME / ABIM MOC Released: 9/29/2023
Valid for credit through: 9/29/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.00 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncology specialists, obstetrician/gynecologists (Ob/Gyns), surgeons, and other healthcare professionals (HCPs) involved in the care of patients with high-risk, hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC).

The goal of this activity is for learners to be better able to implement the most appropriate therapy after determining the risk of recurrence for a patient with HR-positive/HER2-negative EBC.

Upon completion of this activity, participants will:

Compare the prognostic difference for patients with high-risk HR-positive/HER2-negative EBC who receive oral cancer therapies
Select appropriate therapeutic interventions to reduce the risk of recurrence in patients with high-risk, HR-positive/HER2-negative EBC
Determine the challenges associated with the use of adjuvant therapy for patients with HR-positive/HER2-negative EBC

Disclosures

Faculty

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director
Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas, United States

Disclosures

Joyce O'Shaughnessy, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; Agendia; Amgen, Inc.; Aptitude Health; AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; Carrick Therapeutics; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Inc.; Fishawack Health; G1 Therapeutics; GlaxoSmithKline; Genentech; Genzyme Corporation; Gilead Sciences, Inc.; Immunomedics, Inc.; Incyte Corporation; Lilly; Merck; Novartis; Ontada; Pfizer, Inc.; Pharmacyclics, Inc.; Pierre Fabre; Puma Biotechnology; Roche; Samsung Bioepis; Sanofi; Seagen Inc.; Stemline Therapeutics; Theralink; Synthon BV

Aditya Bardia, MD, MPH

Director
Breast Cancer Research
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Aditya Bardia, MD, MPH, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; Immunomedics, Inc.; Lilly; Merck; Mersana; Novartis; Pfizer, Inc.; Philips; Radius Health, Inc.; Sanofi
Research funding from: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Genentech; Gilead Sciences, Inc.; Immunomedics, Inc.; Lilly; Merck; Novartis; Pfizer, Inc.; Radius Health, Inc.

Javier Cortes, MD, PhD

Head, International Breast Cancer Center (IBCC)
Medica Scientia Innovation Research (MedSIR)
Barcelona, Spain

Disclosures

Javier Cortés, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Novartis; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda
Research funding from: Novartis; Pfizer, Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda

Editors

Victoria Phoenix, BS

Medical Education Director, Medscape, LLC

Disclosures

Victoria Phoenix, BS has no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, Medscape, LLC

Disclosures

Tristin Abair, PhD, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's “CME in Support of MOC” program in Section 3 of the Royal College's MOC Program.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Implementing Therapeutic Intervention in High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Understanding the Prognostic Implications

Authors: Joyce O’Shaughnessy, MD; Aditya Bardia, MD, MPH; Javier Cortés, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 9/29/2023

Valid for credit through: 9/29/2024, 11:59 PM EST

processing....

PDF transferível em português

Download the pdf.

Download Now

« Return to: Implementing Therapeutic Intervention in High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Understanding the Prognostic Implications

References

Faculty and Disclosures

Faculty

Joyce O'Shaughnessy, MD

Aditya Bardia, MD, MPH

Javier Cortes, MD, PhD

Editors

Victoria Phoenix, BS

Tristin Abair, PhD

Yoji Yamaguchi, MA, ELS

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME / ABIM MOC

Implementing Therapeutic Intervention in High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Understanding the Prognostic Implications

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Joyce O'Shaughnessy, MD

Aditya Bardia, MD, MPH

Javier Cortes, MD, PhD

Editors

Victoria Phoenix, BS

Tristin Abair, PhD

Yoji Yamaguchi, MA, ELS

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Implementing Therapeutic Intervention in High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Understanding the Prognostic Implications

PDF transferível em português

PDF Downloads